Investing.com - Barclays upgraded Summit Therapeutics plc (NASDAQ:SMMT) from Underweight to Equalweight and raised its price target to $18.00 from $16.00. The new target represents a slight upside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback